Stocktoria
Cadrenal Therapeutics, Inc. CVKD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-01-20
Cadrenal Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $4.1M | $4.2M | $4.1M | $392,859 |
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M |
| Interest expense | — | — | — | $40,192 |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| EPS (diluted) | $-6.64 | $-8.73 | $-9.29 | $-0.85 |
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Cash & equivalents | $4.0M | $10.0M | $8.4M | $32,586 |
| Total assets | $4.3M | $10.1M | $8.5M | $778,174 |
| Total liabilities | $1.6M | $2.7M | $826,875 | $6.3M |
| Shareholders' equity | $2.7M | $7.4M | $7.7M | -$5.6M |
Source: SEC EDGAR filings · CIK 0001937993 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.